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therapies for managing palliative care patients with Opioid
Induced Constipation (OIC). METHODS: The study was con-
ducted by developing and administering a survey composed of a
modiﬁed decision board and a WTP instrument to subjects
recruited from the general public in Ontario, Canada (N = 401).
The decision board described the state of OIC, therapeutic
options and the outcomes and side effects associated with each
option. Participants stated their therapeutic preference and those
who preferred methylnaltrexone were subsequently presented
with a WTP instrument which elicited the hypothetical amount
of money they would be willing to pay out-of-pocket per week
and as additional monthly insurance premium for the therapeutic
option that included methylnaltrexone. Kruskal-Wallis test, Wil-
coxon Rank-Sum test, chi-square tests and multiple linear regres-
sion analysis were performed to assess the inﬂuence of
demographics and other variables on treatment preference and
WTP. RESULTS: Majority of the participants (N = 241) chose
the methylnaltrexone plus laxative regimen as their therapeutic
preference (60% vs. 36%, 4% indifferent). Treatment prefer-
ences were found to be signiﬁcantly different between age groups
(p < 0.001) and education levels (p = 0.021). The mean WTP for
out-of-pocket expenses per week was $163.42 with values
ranging from $0 to $ 2308. The overall mean additional monthly
premium was $8.65. Household income was a signiﬁcant predic-
tor of out of pocket amount (p < 0.05). Other demographic
parameters did not have a signiﬁcant impact on WTP. CONCLU-
SIONS: In this study population, which determined the
maximum WTP for treatment of OIC, most participants were
willing to pay to have methylnaltrexone added to conventional
therapies. The WTP values need to be further incorporated in a
formal cost beneﬁt analysis.
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OBJECTIVES: quality of life (QOL) is an important outcome in
lung patient (LC) treated by chemotherapy. Alopecia may be an
important part of this QOL but in fact very few data’s are
availablethe aim of this study is to assess, in patients treated by
chemotherapy, the impact of alopecia. METHODS: This pro-
spective, single centre study, use a willingness to pay method.
Advanced LC patients were asked ﬁrst to assess the impact of
alopecia in second line chemotherapy setting from an analogical
visual scale (from 0: no impact to 10 major impact); then they
participated, in a face to face interview, at the presentation of a
hypothetical scenario giving the choice between 2 chemothera-
pies with the same efﬁcacy, the same pattern of administration
(every 3 weeks, in day care hospital) and the same tolerability
except for the risk of alopecia : 5% for the product A and 40%
for the product B and were asked for their willingness to pay for
product A. RESULTS: Sixty-four patients had been enrolled
(59%, age : 60,8  10,3 y, married 58%). In analogical visual
scale, the impact of alopecia were assessed at 4,1  3,4. Patients
were willing to pay, for a 3-week chemotherapy cycle, a median
amount of €130,4  151.9 (median 62.5) to receive the product
with the lower rate of alopecia. But 27 (42.2%) are not ready to
pay anything. The patients no willing to pay are more often men
(p < 0.001), no married (p < 0,03), have low income (p < 0,001)
and hairless before treatment (p < 0.001). Correlation between
the results of the analogical visual scale and the willingness to
pay is good. CONCLUSIONS: a limit of this study is the context
of the French health system (universal health coverage) with no
payment by the patient for chemotherapy treatment than the
scenario tested is really hypothetical and may under or over
estimated the real willingness to pay of the participants. Prospec-
tive international studies are needed to conﬁrm these preliminar-
ies results.
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OBJECTIVES:To assess the impact of a cost attribute on prefer-
ences for a surgical treatment, in particular Surgical Excision (SE)
and Mohs Micrographic Surgery (MMS), to remove primary
Basal Cell Carcinoma (BCC). METHODS: Six attributes (recur-
rence, re-excision, travel time, surgical time, waiting time surgi-
cal results, costs) and their levels were selected, based on results
of a clinical trial, a cost-effectiveness study, a review and a focus
group of patients who recently had received treatment for BCC.
Two DCEs, one without (DCE_nocost) and one with a cost
attribute (DCE_cost) were conducted among the general public.
Outcomes of both DCEs were compared in terms of theoretical
validity, relative importance of the attributes and the rank order
of preferences. RESULTS: Except for travel time in DCE_nocost,
respondents in both DCEs valued a surgical treatment with a
lower level for all the selected attributes. Differences in ordering
of attribute importance occurred with the attribute waiting time
surgical results which was third in DCE_nocost and ended as last
in DCE_cost. The incremental utility score for DCE_nocost was
1.497 while the incremental willingness to pay for DCE_cost
amounted to € 847 in DCE_cost, both indicating a preference of
MMS to SE. CONCLUSIONS: From a policy perspective, results
show that the inclusion of a cost-variable does not change the
rank order of preferences for a surgical treatment to remove
BCC. However, the results of our comparison are speciﬁc to the
clinical setting of primary BCC and the surgical procedures MMS
and SE. Further research within different settings will be needed
to conﬁrm our ﬁndings.
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OBJECTIVES: About one in every eight women in The Nether-
lands develops breast cancer. Every year, 11,000 new cases are
registered and about 3500 women die of breast cancer. Prognosis
after primary treatment for patients with breast cancer is improv-
ing. This leads to an increased number of patients in follow-up,
which leads to increased workload. One of the main goals of
follow-up is to improve the survival of patients. This study aims
to determine a more individualized follow-up by modelling cost-
effectiveness of various follow-up scenarios and by determining
individual preferences by using a discrete choice experiment
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